Mr. Hugh MacNaught reports

VENTRIPOINT ANNOUNCES CLOSING OF DEBT SETTLEMENT AGREEMENTS

Ventripoint Diagnostics Ltd. has closed the previously announced shares for debt settlement transactions (see press release dated Nov. 6, 2024) to settle an aggregate of $19,335 of debt owed to a former director and a holding company of the former director of the corporation by issuing an aggregate of 128,900 common shares of the corporation at a deemed price of 15 cents per share. The shares are subject to a hold period of four months and one day. The corporation determined to satisfy the indebtedness with shares in order to preserve its cash for development of its business. Issuance of shares is subject to approval by the TSX Venture Exchange. The shares are subject to a hold period of four months and one day.

About Ventripoint Diagnostics Ltd.

Ventripoint has become an industry leader in the application of AI (artificial intelligence) to echocardiography. Ventripoint's VMS products are powered by its proprietary knowledge-based reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI (magnetic resonance imaging). This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all of Ventripoint's products that guide the company's future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the United States, Europe and Canada.

We seek Safe Harbor.